Welcome to our dedicated page for Milestone Scient news (Ticker: MLSS), a resource for investors and traders seeking the latest updates and insights on Milestone Scient stock.
Milestone Scientific Inc. reports developments tied to computerized drug delivery instruments for dental and medical applications. The company’s Dynamic Pressure Sensing technology supports pressure-guided injection and fluid-aspiration procedures, including dental anesthesia delivery through The Wand STA system and medical applications such as CompuFlo for controlled epidural injections.
Recurring news themes include financial results, business-update calls, commercialization programs, physician and dental-practice adoption, distributor and reimbursement infrastructure, international product registrations, disposable utilization, operating expense initiatives, and capital actions involving common stock and warrants.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Milestone Scientific Inc. (NYSE: MLSS) reported a decline in 2022 revenues of $8.8 million, down from $10.3 million in 2021, attributed mainly to a $1.4 million drop in sales from China and a decrease in domestic dental revenue. The company faced an operating loss of $8.8 million, compared to $7.4 million the previous year. Despite these challenges, Milestone made progress in its product rollout, particularly the CompuFlo® Epidural System, which received FDA clearance for thoracic applications, potentially enhancing its market penetration. The company also launched a new online store for dental products, aiming for improved customer relations and profitability.